{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:03:59Z","timestamp":1784819039718,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The coronavirus disease 2019 (COVID-19) can result in a hyperinflammatory state, leading to acute respiratory distress syndrome (ARDS), myocardial injury, and thrombotic complications, among other sequelae. Statins, which are known to have anti-inflammatory and antithrombotic properties, have been studied in the setting of other viral infections, but their benefit has not been assessed in COVID-19. This is a retrospective analysis of patients admitted with COVID-19 from February 1<jats:sup>st<\/jats:sup> through May 12<jats:sup>th<\/jats:sup>, 2020 with study period ending on June 11<jats:sup>th<\/jats:sup>, 2020. Antecedent statin use was assessed using medication information available in the electronic medical record. We constructed a multivariable logistic regression model to predict the propensity of receiving statins, adjusting for baseline sociodemographic and clinical characteristics, and outpatient medications. The primary endpoint includes in-hospital mortality within 30 days. A total of 2626 patients were admitted during the study period, of whom 951 (36.2%) were antecedent statin users. Among 1296 patients (648 statin users, 648 non-statin users) identified with 1:1 propensity-score matching, statin use is significantly associated with lower odds of the primary endpoint in the propensity-matched cohort (OR 0.47, 95% CI 0.36\u20130.62, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). We conclude that antecedent statin use in patients hospitalized with COVID-19 is associated with lower inpatient mortality.<\/jats:p>","DOI":"10.1038\/s41467-021-21553-1","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T11:03:35Z","timestamp":1614337415000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":137,"title":["Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9103-9872","authenticated-orcid":false,"given":"Aakriti","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7740-1481","authenticated-orcid":false,"given":"Mahesh V.","family":"Madhavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Poterucha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ersilia M.","family":"DeFilippis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Hennessey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn","family":"Redfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Eckhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnood","family":"Bikdeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5615-7328","authenticated-orcid":false,"given":"Ani","family":"Nalbandian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9643-3024","authenticated-orcid":false,"given":"Pierre","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayan N.","family":"Nouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lawlor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2305-156X","authenticated-orcid":false,"given":"Lauren S.","family":"Ranard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Givens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0813-3145","authenticated-orcid":false,"given":"Daniel","family":"Brodie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2046-127X","authenticated-orcid":false,"given":"Harlan M.","family":"Krumholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg W.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjum S.","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Burkhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Uriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin B.","family":"Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay J.","family":"Kirtane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5328-7282","authenticated-orcid":false,"given":"Elaine Y.","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0551-5885","authenticated-orcid":false,"given":"Sahil A.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"21553_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 579, 270\u2013273 (2020).","journal-title":"Nature."},{"key":"21553_CR2","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","volume":"382","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan, M. et al. Renin\u2013angiotensin\u2013aldosterone system inhibitors in patients with Covid-19. N. Engl. J. Med. 382, 1653\u20131659 (2020).","journal-title":"N. Engl. J. Med."},{"key":"21553_CR3","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","volume":"20","author":"MZ Tay","year":"2020","unstructured":"Tay, M. Z., Poh, C. M., R\u00e9nia, L., MacAry, P. A. & Ng, L. F. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immun. 20, 363\u2013374 (2020).","journal-title":"Nat. Rev. Immun."},{"key":"21553_CR4","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jama.2019.20153","volume":"323","author":"JM Sanders","year":"2020","unstructured":"Sanders, J. M., Monogue, M. L., Jodlowski, T. Z. & Cutrell, J. B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 323, 1824\u20131836 (2020).","journal-title":"JAMA."},{"key":"21553_CR5","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195\u20132207 (2008).","journal-title":"N. Engl. J. Med."},{"key":"21553_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","volume":"120","author":"A Oesterle","year":"2017","unstructured":"Oesterle, A., Laufs, U. & Liao, J. K. Pleiotropic effects of statins on the cardiovascular system. Circ. Res. 120, 229\u2013243 (2017).","journal-title":"Circ. Res."},{"key":"21553_CR7","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1055\/s-0040-1713152","volume":"120","author":"B Bikdeli","year":"2020","unstructured":"Bikdeli, B. et al. Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research. Thromb. Haemost. 120, 1004 (2020).","journal-title":"Thromb. Haemost."},{"key":"21553_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.biopha.2016.04.043","volume":"82","author":"F Kong","year":"2016","unstructured":"Kong, F. et al. Atorvastatin suppresses NLRP3 inflammasome activation via TLR4\/MyD88\/NF-kappaB signaling in PMA-stimulated THP-1 monocytes. Biomed. Pharmacother. 82, 167\u2013172 (2016).","journal-title":"Biomed. Pharmacother."},{"key":"21553_CR9","doi-asserted-by":"publisher","first-page":"e0170123","DOI":"10.1371\/journal.pone.0170123","volume":"12","author":"H Guo","year":"2017","unstructured":"Guo, H. et al. The important role of lipid raft-mediated attachment in the infection of cultured cells by coronavirus infectious bronchitis virus beaudette strain. PLoS ONE 12, e0170123 (2017).","journal-title":"PLoS ONE"},{"key":"21553_CR10","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/cr.2008.15","volume":"18","author":"H Wang","year":"2008","unstructured":"Wang, H. et al. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res. 18, 290\u2013301 (2008).","journal-title":"Cell Res."},{"key":"21553_CR11","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.bbrc.2008.02.023","volume":"369","author":"Y Lu","year":"2008","unstructured":"Lu, Y., Liu, D. X. & Tam, J. P. Lipid rafts are involved in SARS-CoV entry into Vero E6 cells. Biochem. Biophys. Res. Commun. 369, 344\u2013349 (2008).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"21553_CR12","doi-asserted-by":"publisher","first-page":"104803","DOI":"10.1016\/j.phrs.2020.104803","volume":"156","author":"M Bifulco","year":"2020","unstructured":"Bifulco, M. & Gazzerro, P. Statins in coronavirus outbreak: It\u2019s time for experimental and clinical studies. Pharmacol. Res. 156, 104803 (2020).","journal-title":"Pharmacol. Res."},{"key":"21553_CR13","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1016\/j.jacc.2020.03.031","volume":"75","author":"E Driggin","year":"2020","unstructured":"Driggin, E. et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J. Am. Coll. Cardiol. 75, 2352\u20132371 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"21553_CR14","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1164\/rccm.200810-1584OC","volume":"179","author":"M Shyamsundar","year":"2009","unstructured":"Shyamsundar, M. et al. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am. J. Respir. Crit. Care Med. 179, 1107\u20131114 (2009).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"21553_CR15","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-2600(18)30177-2","volume":"6","author":"CS Calfee","year":"2018","unstructured":"Calfee, C. S. et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir. Med. 6, 691\u2013698 (2018).","journal-title":"Lancet Respir. Med."},{"key":"21553_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.7861\/clinmedicine.17-5-403","volume":"17","author":"FS Grudzinska","year":"2017","unstructured":"Grudzinska, F. S. et al. Statin therapy in patients with community-acquired pneumonia. Clin. Med. 17, 403\u2013407 (2017).","journal-title":"Clin. Med."},{"key":"21553_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0368-6","volume":"13","author":"A Mansur","year":"2015","unstructured":"Mansur, A. et al. Impact of statin therapy on mortality in patients with sepsis-associated acute respiratory distress syndrome (ARDS) depends on ARDS severity: a prospective observational cohort study. BMC Med. 13, 128 (2015).","journal-title":"BMC Med."},{"key":"21553_CR18","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1097\/CCM.0b013e31821b8290","volume":"39","author":"S Yende","year":"2011","unstructured":"Yende, S. et al. Understanding the potential role of statins in pneumonia and sepsis. Crit. Care Med. 39, 1871\u20131878 (2011).","journal-title":"Crit. Care Med."},{"key":"21553_CR19","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa1403285","volume":"371","author":"DF McAuley","year":"2014","unstructured":"McAuley, D. F. et al. Simvastatin in the acute respiratory distress syndrome. N. Engl. J. Med. 371, 1695\u20131703 (2014).","journal-title":"N. Engl. J. Med."},{"key":"21553_CR20","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa1401520","volume":"370","author":"L National Heart","year":"2014","unstructured":"National Heart, L. et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N. Engl. J. Med. 370, 2191\u20132200 (2014).","journal-title":"N. Engl. J. Med."},{"key":"21553_CR21","doi-asserted-by":"publisher","unstructured":"Gupta, A., Madhavan, M. V. & Sehgal, K. Extrapulmonary manifestations of COVID-19. Nat. Med. (2020) accepted: https:\/\/doi.org\/10.1038\/s41591-020-0968-3.","DOI":"10.1038\/s41591-020-0968-3"},{"key":"21553_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2015432","volume":"383","author":"M Ackermann","year":"2020","unstructured":"Ackermann, M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med 383, 120\u2013128 (2020).","journal-title":"N. Engl. J. Med"},{"key":"21553_CR23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M20-2003","volume":"173","author":"D Wichmann","year":"2020","unstructured":"Wichmann, D. et al. Autopsy findings and venous thromboembolism in patients With COVID-19: a prospective cohort study. Ann. Intern. Med. 173, 268\u2013277 (2020).","journal-title":"Ann. Intern. Med."},{"key":"21553_CR24","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","volume":"395","author":"Z Varga","year":"2020","unstructured":"Varga, Z. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 395, 1417\u20131718 (2020).","journal-title":"Lancet."},{"key":"21553_CR25","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1001\/jama.2020.8907","volume":"323","author":"T Schaller","year":"2020","unstructured":"Schaller, T. et al. Postmortem examination of patients with COVID-19. JAMA. 323, 2518\u20132520 (2020).","journal-title":"JAMA."},{"key":"21553_CR26","doi-asserted-by":"crossref","unstructured":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383\u20131389 (1994).","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"21553_CR27","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1600177","volume":"374","author":"S Yusuf","year":"2016","unstructured":"Yusuf, S. et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N. Engl. J. Med. 374, 2032\u20132043 (2016).","journal-title":"N. Engl. J. Med."},{"key":"21553_CR28","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","volume":"54","author":"P Libby","year":"2009","unstructured":"Libby, P., Ridker, P. M. & Hansson, G. K. Leducq Transatlantic Network on Atherothrombosis Inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol. 54, 2129\u20132138 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"21553_CR29","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1093\/eurheartj\/ehu203","volume":"35","author":"PM Ridker","year":"2014","unstructured":"Ridker, P. M. & Luscher, T. F. Anti-inflammatory therapies for cardiovascular disease. Eur. Heart J. 35, 1782\u20131791 (2014).","journal-title":"Eur. Heart J."},{"key":"21553_CR30","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/nrd1901","volume":"4","author":"MK Jain","year":"2005","unstructured":"Jain, M. K. & Ridker, P. M. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat. Rev. Drug Discov. 4, 977\u2013987 (2005).","journal-title":"Nat. Rev. Drug Discov."},{"key":"21553_CR31","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","volume":"365","author":"SJ Nicholls","year":"2011","unstructured":"Nicholls, S. J. et al. Effect of two intensive statin regimens on progression of coronary disease. N. Engl. J. Med. 365, 2078\u20132087 (2011).","journal-title":"N. Engl. J. Med."},{"key":"21553_CR32","doi-asserted-by":"publisher","first-page":"e005934","DOI":"10.1161\/CIRCIMAGING.116.005934","volume":"10","author":"O Kwon","year":"2017","unstructured":"Kwon, O. et al. Relationship between serum inflammatory marker levels and the dynamic changes in coronary plaque characteristics after statin therapy. Circ. Cardiovasc. Imaging 10, e005934 (2017).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"21553_CR33","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/S2352-3026(16)30184-3","volume":"4","author":"SK Kunutsor","year":"2017","unstructured":"Kunutsor, S. K., Seidu, S. & Khunti, K. Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis. Lancet Haematol. 4, e83\u2013e93 (2017).","journal-title":"Lancet Haematol."},{"key":"21553_CR34","unstructured":"Prescribing information. Brilinta (ticagrelor). Wilmington, DE: AstraZeneca LP, 07\/2011."},{"key":"21553_CR35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Z Jin","year":"2020","unstructured":"Jin, Z. et al. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature 582, 289\u2013293 (2020).","journal-title":"Nature"},{"key":"21553_CR36","doi-asserted-by":"publisher","first-page":"490","DOI":"10.5114\/aoms.2020.94655","volume":"16","author":"Z Reiner","year":"2020","unstructured":"Reiner, Z. et al. Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch. Med. Sci. 16, 490\u2013496 (2020).","journal-title":"Arch. Med. Sci."},{"key":"21553_CR37","doi-asserted-by":"publisher","first-page":"4942","DOI":"10.1111\/bph.15094","volume":"177","author":"SPH Alexander","year":"2020","unstructured":"Alexander, S. P. H. et al. A rational roadmap for SARS-CoV-2\/COVID-19 pharmacotherapeutic research and development. IUPHAR Review 29. Br. J. Pharmacol. 177, 4942\u20134966 (2020).","journal-title":"Br. J. Pharmacol."},{"key":"21553_CR38","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00134-016-4649-0","volume":"43","author":"M Nagendran","year":"2017","unstructured":"Nagendran, M. et al. Statin therapy for acute respiratory distress syndrome: an individual patient data meta-analysis of randomised clinical trials. Intensive Care Med. 43, 663\u2013671 (2017).","journal-title":"Intensive Care Med."},{"key":"21553_CR39","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1097\/CCM.0b013e3182120992","volume":"39","author":"HR O\u2019Neal Jr.","year":"2011","unstructured":"O\u2019Neal, H. R. Jr. et al. Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury\/acute respiratory distress syndrome. Crit. Care Med. 39, 1343\u20131350 (2011).","journal-title":"Crit. Care Med."},{"key":"21553_CR40","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s00134-018-5378-3","volume":"44","author":"P Sinha","year":"2018","unstructured":"Sinha, P. et al. Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. Intensive Care Med. 44, 1859\u20131869 (2018).","journal-title":"Intensive Care Med."},{"key":"21553_CR41","doi-asserted-by":"publisher","first-page":"S296","DOI":"10.21037\/jtd.2019.01.23","volume":"11","author":"NFL Heijnen","year":"2019","unstructured":"Heijnen, N. F. L., Bergmans, D., Schnabel, R. M. & Bos, L. D. J. Targeted treatment of acute respiratory distress syndrome with statins-a commentary on two phenotype stratified re-analysis of randomized controlled trials. J. Thorac. Dis. 11, S296\u2013S299 (2019).","journal-title":"J. Thorac. Dis."},{"key":"21553_CR42","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jacc.2020.05.001","volume":"76","author":"I Paranjpe","year":"2020","unstructured":"Paranjpe, I. et al. Association of treatment dose anticoagulation with inhospital survival among hospitalized patients with COVID-19. J. Am. Coll. Cardiol. 76, 122\u2013124 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"21553_CR43","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jamda.2020.06.018","volume":"21","author":"A De Spiegeleer","year":"2020","unstructured":"De Spiegeleer, A. et al. The effects of ARBs, ACEIs and statins on clinical outcomes of COVID-19 infection among nursing home residents. J. Am. Med. Dir. Assoc. 21, 909\u2013914 (2020).","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"21553_CR44","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cmet.2020.06.015","volume":"32","author":"XJ Zhang","year":"2020","unstructured":"Zhang, X. J. et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab 32, 176\u2013187 (2020).","journal-title":"Cell Metab"},{"key":"21553_CR45","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.amjcard.2020.08.004","volume":"134","author":"CS Kow","year":"2020","unstructured":"Kow, C. S. & Hasan, S. S. Meta-analysis of effect of statins in patients with COVID-19. Am. J. Cardiol. 134, 153\u2013155 (2020).","journal-title":"Am. J. Cardiol."},{"key":"21553_CR46","unstructured":"Onorato, D. et al. Protective effects of statins administration in European and North American patients infected with COVID-19: a meta-analysis. Semin. Thromb. Hemost. (2021)."},{"key":"21553_CR47","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.thromres.2020.09.027","volume":"196","author":"B Bikdeli","year":"2020","unstructured":"Bikdeli, B. et al. Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: rationale and design of the INSPIRATION\/INSPIRATION-S studies. Thromb. Res. 196, 382\u2013394 (2020).","journal-title":"Thromb. Res."},{"key":"21553_CR48","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/S0140-6736(20)31189-2","volume":"395","author":"MJ Cummings","year":"2020","unstructured":"Cummings, M. J. et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 395, 1763\u20131770 (2020).","journal-title":"Lancet."},{"key":"21553_CR49","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","volume":"382","author":"HR Reynolds","year":"2020","unstructured":"Reynolds, H. R. et al. Renin-angiotensin-aldosterone system inhibitors and risk of covid-19. N. Engl. J. Med. 382, 2441\u20132448 (2020).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21553-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21553-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21553-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T10:55:34Z","timestamp":1669978534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21553-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["21553"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-21553-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]},"assertion":[{"value":"24 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.G. received payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation and from the Ben C. Martin Law Firm for work related to an inferior vena cava filter litigation; received consulting fees from Edward Lifesciences; and holds equity in the healthcare telecardiology startup Heartbeat Health. M.V.M. has received support from an institutional grant by the National Institutes of Health\/National Heart, Lung, and Blood Institute to Columbia University Irving Medical Center (T32 HL007854). B.B. reports that he is a consulting expert, on behalf of the plaintiff, for litigation related to a specific type of IVC filter. M.J.C. reports being a co-investigator for clinical trials evaluating the efficacy and safety of Remdesivir (Gilead Sciences) and convalescent plasma (Amazon) in hospitalized patients with COVID-19. Support for this work, which is unrelated to the current study, is paid to Columbia University. D.B. receives research support from ALung Technologies, he was previously on their medical advisory board. He has been on the medical advisory boards for Baxter, BREETHE, Xenios and Hemovent. G.W.S. reports speaker or other honoraria from Cook, Terumo, QOOL Therapeutics and Orchestra Biomed; Consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, Matrizyme, Cardiomech; equity\/options from Ancora, Qool Therapeutics, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, MedFocus family of funds, and Valfix. T.J.P. owns stock in Abbott Laboratories, AbbVie, Inc, Baxter International, and Edwards Lifesciences. H.M.K. works under contract with the Centers for Medicare & Medicaid Services to support quality measurement programs; was a recipient of a research grant, through Yale, from Medtronic and the U.S. Food and Drug Administration to develop methods for post-market surveillance of medical devices; was a recipient of a research grant with Medtronic and is the recipient of a research grant from Johnson & Johnson, through Yale University, to support clinical trial data sharing; was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, from the Ben C. Martin Law Firm for work related to the Cook Celect IVC filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a participant\/participant representative of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; and is the co-founder of HugoHealth, a personal health information platform, and co-founder of Refactor Health, an enterprise healthcare AI-augmented data enterprise. Other authors report no disclosures. A.J.K. reports institutional funding to Columbia University and\/or Cardiovascular Research Foundation from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, Philips, ReCor Medical.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1325"}}